Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
TroFuse-032
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- NCT06966700 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on TroFuse-032 (sacituzumab tirumotecan, pembrolizumab and 8 more in Breast Neoplasms) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TroFuse-032 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 3 | |
| X threads | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
- Interventions
- Sacituzumab tirumotecan; Pembrolizumab; Rescue Medication; Carboplatin; Paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide; Capecitabine; Olaparib
- Arms
- sac-TMT · Experimental
- Chemotherapy · Active comparator
- Enrollment
- 2,400 (estimated)
- Primary outcomes
- Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery
- Event-Free Survival (EFS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Jun 30, 2025
- Primary completion
- Mar 23, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT06966700 · updated Oct 13, 2026
Publications
linked from the registry- Schmid P, Cortes J, Hui R, Masuda N, Garrido-Castro AC, Loirat D, Shao ZM, Park YH, Wei J, Beca F, Malhotra U, Harbeck N. TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer. Future Oncol. 2026 Oct 14:1-11. doi: 10.1080/14796694.2026.2732590. Online ahead of print. PubMed 42872715